Singapore markets closed
  • Straits Times Index

    3,205.14
    +16.64 (+0.52%)
     
  • Nikkei

    28,804.85
    +96.27 (+0.34%)
     
  • Hang Seng

    26,126.93
    +109.40 (+0.42%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • BTC-USD

    60,979.98
    -2,235.66 (-3.54%)
     
  • CMC Crypto 200

    1,453.34
    -49.69 (-3.31%)
     
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow

    35,677.02
    +73.94 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • Crude Oil

    83.98
    +1.48 (+1.79%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • FTSE Bursa Malaysia

    1,588.08
    -3.54 (-0.22%)
     
  • Jakarta Composite Index

    6,643.74
    +10.77 (+0.16%)
     
  • PSE Index

    7,289.61
    -22.11 (-0.30%)
     

How Will Valneva's COVID Vaccine Setback Impact Dynavax?

·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Several companies are using CpG 1018, an adjuvant developed by Dynavax Technologies (NASDAQ: DVAX), in developing their COVID-19 vaccines. One of them, French biotech Valneva (NASDAQ:VALN), has recently received some bad news with the U.K. canceling a supply deal. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss how Valneva's setback might impact Dynavax.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting